{
  "ticker": "RAD",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02973056",
  "id": "02973056",
  "pages": 2,
  "price_sensitive": true,
  "date": "20250728",
  "time": "0826",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250728/pdf/06m627vh7w5ggz.pdf",
  "summary": "- **FDA IND Approval**: U.S. FDA cleared Investigational New Drug (IND) application for **Betabart (RV-01)**, a Lu177-B7H3 monoclonal antibody targeting the 4Ig isoform of B7-H3 in solid tumors.  \n- **Phase 1 Trial Timeline**: First-in-human study for RV-01 **on track to initiate in Q4 2025**.  \n- **Key Differentiation**: RV-01\u2019s hepatic clearance may reduce hematological/kidney toxicity risks vs. renal-excreted radiopharmaceuticals.  \n- **Target Significance**: B7-H3 is an immune checkpoint overexpressed in aggressive tumors, linked to poor prognosis.  \n\n(*No capital markets or trading-specific actions announced.*)",
  "usage": {
    "prompt_tokens": 1518,
    "completion_tokens": 155,
    "total_tokens": 1673,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-07-27T22:38:59.252612"
}